CytoResc - CytoSorb Rescue for COVID-19 Cytokine Storm
Phase 2
- Conditions
- U07.1COVID-19, virus identified
- Registration Number
- DRKS00021447
- Lead Sponsor
- Charité Campus Virchow-Klinikum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Males or females aged 18-80, Positive PCR test for SARS-CoV-2, Vasoplegic shock (Noradrenalin > 0.2 µg/min/kg (aiming MAD = 65mmHg), CRP > 100 mg/l, Indication for hemodialysis
Exclusion Criteria
Patients receiving Tocilizumab (anti-IL6-receptor antibody), Pregnancy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method time to resolution of vasoplegic shock (defined as no need for vasopressors for at least 8 hours in order to sustain a MAD = 65mmHg) in days
- Secondary Outcome Measures
Name Time Method 7 day mortality after fulfilling the inclusion criteria, mortality until hospital discharge, IL-6 measurement on day 1 and 3, need for mechanical ventilation, duration of mechanical ventilation, duration of ICU-stay, catecholamine dose on day 1/2/3 after start of CytoSorb, acute kidney injury